Invasive procedures to biopsy tissue from cancer-tainted organs could be replaced by simply taking samples from a tiny “decoy” implanted just beneath the skin, University of Michigan researchers have demonstrated in mice.
These devices have a knack for attracting cancer cells traveling through the body. In fact, they can even pick up signs that cancer is preparing to spread, before cancer cells arrive.
“Biopsying an organ like the lung is a risky procedure that’s done only sparingly,” said Lonnie Shea, the William and Valerie Hall Chair of biomedical engineering at U-M. “We place these scaffolds right under the skin, so they’re readily accessible.”
The ease of access would also allow doctors to monitor the effectiveness of cancer treatments closer to real time.
The U-M team’s most recent work appears in Cancer Research, a publication of the American Association for Cancer Research.
Biopsies of the scaffold allowed researchers to analyze 635 genes present in the captured cancer cells. From these genes, the team identified ten that could predict whether a mouse was healthy, if it had a cancer that had not begun to spread yet, or if a cancer was present and had begun to spread. They could do that all without the need for an invasive biopsy of an organ.
The gene expression obtained at the scaffold had distinct patterns relative to cells from the blood, which are obtained through a technique known as liquid biopsy. These differences highlight that the tissue in these traps provides unique information that correlates with disease progression.
The researchers have demonstrated that the synthetic scaffolds work with multiple types of cancers in mice, including pancreatic cancer. They work by luring immune cells, which, in turn, attract cancer cells.
“When we started off, the idea was that we would biopsy the scaffold and look for tumor cells that had followed the immune cells there,” Shea said. “But we realized that by analyzing the immune cells that gather first, we can detect the cancer before it’s spreading.”
In treating cancer, early detection is key.
“Currently, early signs of metastasis can be difficult to detect,” said Jacqueline Jeruss, an associate professor of surgery and biomedical engineering and a co-author of the study. “Imaging may be done once a patient experiences symptoms, but that implies the number of cancer cells may already be substantial. Improved detection methods are needed to identify metastasis at a point when targeted treatments can have a significant beneficial impact on slowing disease progression.”
The immune cells allowed researchers to identify whether treatments were effective in the mice and which subjects were sensitive or resistant to treatment.
The decoy’s ability to draw immune and cancer cells can also bolster the treatment itself. In previous research, the devices demonstrated an ability to slow the growth of metastatic breast cancer tumors in mice, by reducing the number of cancer cells that can reach those tumors.
In the future, Shea envisions that the scaffolds could be outfitted with sensors and Bluetooth technology that could deliver information in real time without the need for a biopsy.
Learn more: Implantable cancer traps could provide earlier diagnosis, help monitor treatment
The Latest on: Biopsies
[google_news title=”” keyword=”biopsies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Biopsies
- Breakthrough urine test could help men avoid unnecessary prostate biopsieson April 26, 2024 at 9:35 pm
A new urine test for prostate cancer detection is showing promise. The current standard test, the Prostate Specific Antigen, PSA, isn't very accurate at distinguishing between aggressive and ...
- APCCC 2024: When to Do Tumor Genomic Profiling in Advanced Prostate Cancer and What?on April 26, 2024 at 3:55 pm
Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a session on the management of metastatic CRPC (mCRPC), and a presentation by Dr. Niven Mehra discussing when we should do tumor ...
- Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcripton April 26, 2024 at 5:15 am
Q1 2024 Earnings Call Transcript April 24, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.26, expectations were $-0.27. Viking Therapeutics, Inc. isn’t one of the 30 ...
- Companies see value in bringing doctors' offices to the workplaceon April 24, 2024 at 6:36 pm
According to OnSpot Dermatology, its mobile clinic offers everything a brick-and-mortar office does, including treatments for various skin conditions, biopsies.
- New Urine Test for Prostate Cancer May Help Reduce Unnecessary Biopsieson April 22, 2024 at 4:19 am
A prostate cancer biomarker test that utilizes genes indicating high-grade prostate cancer appears highly accurate.
- New prostate cancer test to help avoid unnecessary biopsieson April 20, 2024 at 11:48 pm
A new urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests.
- Avoid Unnecessary Biopsies: New Urine-Based Test Detects High-Grade Prostate Canceron April 19, 2024 at 6:22 pm
New urine-based test looks at 18 genes and was specifically developed to pick out those cancers that need immediate treatment over the slow-growing type. Researchers at the University of Michigan Roge ...
- Urine Test Might Help Men Skip Prostate Biopsieson April 19, 2024 at 12:00 am
“Four of 10 men who would have a negative biopsy will have a low risk MPS2 result and can confidently skip a biopsy," Wei said. "If a man has had a biopsy before, the test works even better," he added ...
- New urine test has higher diagnostic accuracy for prostate canceron April 18, 2024 at 10:11 am
A new urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to ...
- Study finds promising biomarker for cellular rejection after organ transplanton April 18, 2024 at 7:19 am
Today, patients who receive an organ transplant need repeated surgical biopsies to test for acute cellular rejection (ACR) throughout their lifetimes. But a blood test for ACR could be on the horizon ...
via Bing News